Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: Comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease

British Journal of Radiology

Volumn 85, Issue 1014, 2012, Pages 720-728

  Punwani, S ^a   Emberton, M ^a   Walkden, M ^a   Sohaib, A ^b   Freeman, A ^a   Ahmed, H ^a   Allen, C ^a   Kirkham, Alex ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DATA BASE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84861578835     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/61380797     Document Type: Article

References (19)

1. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004;63:297-300. (Pubitemid 38234422)
2. Colombel M, Gelet A. Principles and results of high-intensity focused ultrasound for localized prostate cancer. Prostate Cancer Prostatic Dis 2004;7:289-94. (Pubitemid 41721785)
3. Shoji S, Nakano M, Nagata Y, Usui Y, Terachi T, Uchida T. Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int J Urol 2010;17:715-19.
4. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008;53:1194-201.
5. Riviere J, Bernhard JC, Robert G, Wallerand H, Deti E, Maurice-Tison S, et al. Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer. Eur Urol 2010;58:567-73.
6. Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 2008;190:1180-6. (Pubitemid 351684917)
7. Polascik TJ, Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology 2009;74:726-30.
8. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176:2432-7. (Pubitemid 44665992)
9. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:425-30.
10. 2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 2010;20:48-55.
11. Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M. Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int 2006;98:1187-92. (Pubitemid 44721222)
12. Kirkham APS, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 2008;246:833-44.
13. Fleiss JL. Statistical methods for rates and proportions. Chichester, UK: Wiley; 1981.
14. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43. (Pubitemid 13033817)
15. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MR imaging of the prostate in clinical practice. MAGMA 2008;21:379-92.
16. Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, et al. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009;104:1058-62.
17. Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adeno-carcinoma of the prostate? BJU Int 2006;98:537-9. (Pubitemid 44185871)
18. Kirkham APS, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50:1163-74.
19. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001;166:1679-83.